The AI Arms Race: How AI is Impacting R&D and Enabling Super-Fast Followers

Transcript of panel, recorded Monday, November 9, 2026, at IPWatchdog Studios

This panel conversation took place Monday, November 9, 2026, at IPWatchdog Studios at the fifth annual Life Sciences Masters™ conference hosted by IPWatchdog, Inc. The transcript below was verified on November 15, 2026 (by Gene Quinn) against the IPWatchdog video uploaded to our YouTube Channel, titled “AI and Drug Patents: Are Super-Fast Followers a Threat to Innovation.”

Editorial Summary by IPWatchdog: The panel explores how artificial intelligence is reshaping life sciences R&D and enabling “super-fast followers” to build rapidly on publicly disclosed pharmaceutical research. At stake is the balance between accelerating the development of new medicines and preserving the economic incentives that make pioneering discoveries possible. The discussion examines whether AI-assisted patent scraping threatens the patent bargain or accelerates the follow-on innovation the system is designed to encourage. The panel debates the difficulty of securing broad patent protection after Amgen v. Sanofi, the role of Section 112’s enablement and written description requirements, and how increasingly capable AI tools could affect obviousness and human inventorship. Throughout, the speakers distinguish legitimate competitive advances from unsupported filings and question whether proposed policy responses could undermine innovators’ own use of AI. A central takeaway is to become your own fast follower: use AI to anticipate competing variants, strengthen supporting disclosures, and pursue further innovation before competitors capitalize on published research. The conversation highlights the value of documenting human conception, developing evidence of unexpected results, and aligning patent strategy with the science needed to support meaningful claim scope. It is a timely examination of how innovators can protect research investment while harnessing the technology that is changing the competitive landscape.

Moderator: Gene Quinn, Founder and CEO, IPWatchdog, Inc. Mr. Quinn is a patent attorney and a leading commentator on patent law and innovation policy. He has twice been named one of the top 50 most influential people in IP, and has numerous times been recognized as one of the top 300 IP strategists in the world. Mr. Quinn founded IPWatchdog.com in 1999. According to IAM Magazine, he “has reshaped the IP debate in the United States in a way that has forced policy makers to carefully consider the macroeconomic effects of IP law and its potential to drive innovation and economic activity.” Regarded as an expert on patent eligibility and U.S. patent law and procedure, he has advised inventors, entrepreneurs, and start-up business throughout the U.S. and around the world.

TRANSCRIPT

[Renee Quinn] (0:00 – 0:12)

Hello everyone, welcome to IPWatchdog Unleashed, where each week we journey into the world of intellectual property to discuss the laws, news, policy, and politics of innovation, technology, and creativity.

[Gene Quinn] (0:12 – 3:19)

Hello everyone and welcome, thank you for joining us. Today we’re going to discuss a particular aspect of the ongoing AI arms race, asking how AI is impacting research and development in a particular, and how AI is enabling super-fast followers. As you no doubt already appreciate, artificial intelligence has immense promise. In fact, it is entirely possible that AI could help deliver the next generation of life-saving medicines. It’s also equally possible that AI could weaken the economic foundation that makes discovering groundbreaking medicines possible. The concern is emerging class known as super-fast followers.

These competitors are positioned to mine newly published patent applications in scientific literature, identify opportunities around disclosed inventions, and rapidly pursue related candidates and patent filings. Such activity has the potential to create freedom to operate problems, and enable the super-fast followers to leverage disclosures generated through years of expensive pioneering research. Today we’ll explore how AI is changing R&D, competitive intelligence, patent filing behavior, and disclosure strategy, and what innovators can do to protect the value of research that competitors can now analyze and build upon almost instantly.

Joining me for this conversation is Emily Johnson, who is head of global intellectual property policy and innovation law at Bristol-Myers Squibb. Prior to joining BMS, Emily represented biopharmaceutical companies in patent litigations and appeals, and she served as the head of IP policy and advocacy at Amgen.

We also have Nicholas Lanzatella, who’s a registered patent attorney and principal with Schwegman, Lundberg, and Woessner. Nicholas is a PhD in organic chemistry from the University of Minnesota, and he brings the prosecution perspective to our conversation today.

Also joining us is Kwame Mensah, who holds a PhD in biological sciences from Northwestern University, and who currently serves as assistant general counsel for cell therapy at AstraZeneca, where he has been for more than a decade in various senior leadership roles. Prior to joining AstraZeneca, Kwame was IP counsel for MedImmune, and before that, he was an attorney at MBHB, where among other things, he wrote for the award-winning Patent Docs blog.

And last but not least is Corey Salzberg, who is vice president and global head of IP affairs for Novartis, a position that he held for more than a decade. Corey also serves on the board of the Intellectual Property Owners Association, and he served as president of the Federal Circuit Bar Association during the 2025-2026 term.

Gentlemen and lady, I’m going to start with a broad open-ended question, and maybe we can just go down the line. Corey, we’ll start with you. Where do you want to start this conversation today? What do you want to install in the head of the listener and the attendee here today about this AI arms race and super-fast followers?

[Corey Salsberg] (3:19 – 4:35)

Yeah, so I won’t go into the details yet. I’ll save that, but I think, you know, high level, big picture, we are always concerned when we see developments that have the potential to threaten the patent system that has worked so well for almost 240 years in this country and has survived three industrial revolutions before this one. So that, you know, it should be a given, but I think it’s an important starting point, and I want to kind of start with that understanding.

However, we view this, what has been called patent scraping, this idea of, you know, using AI and maybe other tools to quickly look at published information and create competing patent applications as something that is an incredibly complex issue. There’s a lot of nuance there. There’s a lot of danger and risk if you don’t look at it the right way and start to fashion supposed solutions for something that may not even be a problem.

And I would actually start with the premise, which maybe we’ll circle back around to, because I want everyone else to answer your first question first, of is this even really happening? Is it really happening in the way that everyone is suggesting it is happening? And is it really an AI issue? Is it really a China issue? And is it really a patent issue at all? So, I lay that all on the table. There’s a lot there.

[Gene Quinn] (4:36 – 4:46)

Yes, yes, and yes, but we’ll come back to that. So, we do have some disagreement here among the panel, and we have those guys, and then we have us here who are going to be more correct than those guys.

[Kwame Mensah] (4:48 – 5:30)

So, the thing I’d like everyone to remember is that we, you know, first and foremost are patent practitioners, right? And our job is to create ways to cover the innovations that our companies or clients provide. So, the question is, how do we function in this new environment, whether it’s a China problem or not, whether it’s a patent problem or not, whether it’s a, you know, government problem or not.

I think our job as patent practitioners is to think about, as Corey said, solutions, and to be solution oriented. So, you know, the approach has to be rooted in reality. We are where we are with AI.  We are where we are with innovation. And to Corey’s question, or to Corey’s point, like, is this even different?

[Gene Quinn] (5:31 – 5:39)

So, there you go being reasonable. I did not ask you to be on this panel to be reasonable. I’ll be unreasonable later.

[Kwame Mensah] (5:40 – 5:41)

Okay, that’s coming.

[Gene Quinn] (5:41 – 5:52)

Okay, good. Thanks. We’ve been friends for a very, very long time, and it’s good to have you guys up here on the stage.

So, Emily, can you set the record straight now and put us on the straight and narrow here?

[Emily Johnson] (5:52 – 7:14)

Okay. Well, I will agree with you, Gene, that this has a potential to be a very large problem for the patent system. The patent bargain is, you know, directly implicated by this type of behavior.

For as long as we can remember, when innovators disclose their inventions in a patent application and explain how to make and use their invention, that’s an exchange for a period of exclusivity. And we like that patent bargain because it puts discoveries into the public domain, and it allows people to build upon them and promote the progress of science. The problem is that when patent scrapers use those public disclosures of discoveries to take a shortcut without actually adding something to the science, they can undermine that bargain.

And so, we will get into the examples that we’ve seen. I think we’re still in early days, and we’re not exactly sure how this is going to play out in the long run. But, you know, if this is not addressed in the right way, it does have the potential to unbalance the patent bargain and prevent innovators from disclosing their inventions to the public.

[Gene Quinn] (7:15 – 7:17)

Okay. Great. Thanks, Emily. And Nicholas?

[Nicholas Lanzatella] (7:18 – 10:25)

Yeah. A little background first. I feel like a little bit of an odd duck up here because I’m the only attorney from a law firm, whereas everyone else is in-house. I’ll tell you how I think I can contribute to this discussion. I’m very into AI. I happen to have the privilege to work with a firm, SLW, that’s very tech forward.

For the last three years, I’ve had enterprise access to all the different AI tools. And, you know, three years ago, I used AI occasionally. Two years ago, it was more often than that. And, you know, as of right now, I use AI continuously all day to do my job, which is mostly patent preparation, prosecution, and preparing legal opinions. It has massively changed the way I do my job because I interact with it constantly. I’m a keen observer of how quickly it’s gotten better. Two years ago, I predicted a linear increase in AI, the same way that computers developed throughout my lifetime. I don’t think that’s what’s happening at all. It’s accelerating really, really fast.

And it continually blows me away at what I can do with it and how it can help me improve work quality and do work faster. So as far as first followers, you know, I think they basically come in two flavors. One type of first follower has a product already being developed in a pipeline and a disclosure made by a pharmaceutical company triggers ideas for them to help add on to proprietary knowledge they have.

And they might rapidly file, inspired by knowledge that’s internal to that company. You can maybe call this a builder type of fast follower. A different kind of fast follower is one that just sits at a computer terminal and doesn’t have any research in progress, and only uses AI to flesh out variants, for example, of a pioneer filing and files on that.

I mean, I think that there’s things we can do that pharmaceutical companies can do to deal with the pure filer, the non-pipeline product. And I mean, I think the major theme of what I have to say is, you know, if I was advising a pharmaceutical company, I would advise them to be their own fast follower. I mean, I think that more than anything else, what’s happening here is a sign of the incredibly rapid acceleration of AI.

And what happens when somebody uses it and somebody else doesn’t, it leads to a disadvantage. And I think that, you know, at least as far as a pure filer who’s just sitting there with a computer terminal, they don’t have any tools that major pharmaceutical companies don’t also have access to. I really just think it’s a problem of people spending more money and time with AI in order to counter it and become their own fast follower.

[Gene Quinn] (10:26 – 13:32)

So, I know I’ve set this up as we’ve got this disagreement and that, you know, Kwame and Corey don’t really understand and we’ll educate them about this issue. But I think what’s really going to happen here is we’re going to find as we unfold this conversation, we’re really in vehement agreement. And our disagreement is probably so narrow that you could split it with a hair, maybe.

Because I would agree with what Corey and Kwame said, whether we like it or not, this is just the way that it is. And I agree with what Nicholas said about how pharmaceutical companies need to be their own fast follower and prepare for this. And I am worried probably more so than those three and would find myself in more agreement with Emily about, well, what does this mean?

And I don’t know that we know for sure. Where I am concerned, in my initial thought, is I’m just confident the patent office is going to get it wrong. So, when I say that I disagree with these guys and I agree with Emily more so than any of the others, I think.

But for me, the way I come at this is, look, the patent office is going to screw this up under 112, I’m sure about it. And the way I see them screwing it up, I think Nicholas just kind of alluded to here with the two different classes of fast follower. And you could envision a world where the fast follower who is just sitting at a computer using AI to spit out hypothetical after hypothetical after hypothetical might make it very difficult for a true pioneering groundbreaking innovation to wind up being able to be patented later on, when in fact all they were doing was essentially just throwing every combination up there, didn’t know what would work, didn’t know what wouldn’t work. Because in some of those cases, sure, there will be, you know, like you see a pile in a barn, the little girl runs up and says, there’s got to be a pony here somewhere, right?

We’ve all heard that story. And if you do that in a filing, you throw it all up against the wall, there’ll be something there, that’s correct. But now, have we matured in our way of looking at disclosure such that you can look at what they file and say, well, 95% of this is just garbage, you know, it just wouldn’t work.

They clearly didn’t have anything, there’s no inventor there, which we’ll talk about that issue in a minute. And that 95% just hides the 5% that would work. Or are we going to look at the 5% that, you know, is you put enough monkeys in a room on a typewriter, they will type out eventually Moby Dick, one of them, right, word for word, if they have enough time.

That’s, again, these are logic games that we’re all familiar with, right? So is that then the monkey that can type out Moby Dick, after you have, you know, a million monkeys and a million hours of them hitting typewriters, is that going to make something that, you know, Novartis or AstraZeneca or BMS comes up with and has the science to prove it works, not patentable. And I worry about that.

That’s the piece that I worry about in this whole issue.

[Kwame Mensah] (13:32 – 15:11)

So, I’ll talk a little bit about the patent office. I don’t necessarily think they’re going to get it wrong, because the key fast follower we’re worried about is the person sitting at a computer terminal that just fires out a bunch of structures or fires out a bunch of proteins with no data supporting activity, binding coefficients, etc. I would posit that most of you out here have not had claims granted without data.

Does anyone? Can you raise your hand if you have, because I’ll come find you and you can teach me some things. Ultimately, you have to have data to back these things up.

And we found that you can get over disclosure arguments, you know, the typical laundry list problem, right, where they list every disease state, every combination, etc., by having your own data to overcome those things. So, if the patent office continues to enforce enablement in the way that’s currently doing, I don’t think this is as big of an issue, because of the difficulty of getting claims in the biotech space when you don’t have data. The second part of that, as patent practitioners, is that we need to think about building our patent applications in a way that tell an enablement and a written description story.

I think we get very focused on, here’s our drug, here’s what I’m going to cover, this is what’s on the label, and all that is absolutely mission number one, right? But if we want to put ourselves in a competitive situation and a competitive posture against these following companies and fast followers and innovators, we need to think more broadly about scientific disclosure and have disclosure that will stand up to our own enablement, right? So, it’s a two-part thing, but I don’t have the same kind of fear about the patent office necessarily as maybe you, Gene.

[Gene Quinn] (15:12 – 15:14)

Corey, I saw you shaking your head in agreement.

[Corey Salsberg] (15:14 – 18:46)

Yeah, I mean, I agree with all that. I mean, I think we’re talking about these extreme, I would call them hypotheticals at this point. I think that’s where I’d like to just back up for a minute and say, where are we now?

Because we can talk about what might be in the future, and we should do that too, so let’s save that. But where are we now? There’s been all this talk about patent scraping being a big problem today, and it’s happening left and right all over the place.

Maybe it is, maybe it isn’t. Maybe there’s a bunch of things that we don’t know about yet that we’ll see next year or the year after when things start to publish, right? Applications that have been filed by that person at the desk doing nothing more.

But when you actually dissect the examples that have been held up to date, I think the whole premise starts to break down. So, the first thing is, is this kind of fast following of copying around the margins, is that an AI issue? Not really.

I mean, this has been happening for decades. The examples that people often point to now, some recent ones, actually started, if you look back at the prosecution history, five, six years ago, there were no AI tools that most people were using for large language-type generation tools at that point. So now that you’re starting to see these assets that are similar to the lead asset being put into a lab in China somewhere, just because that’s happening doesn’t mean that AI is there.

Second, is it a China issue? Well, actually, if you look at where a lot of these entities are incorporated and where they started, one of the biggest companies in the examples that are pointed to is a company called Insilico Medicines, which is a company founded in 2014 in Cambridge, Massachusetts, by, I think, a European guy who trained at Johns Hopkins and has been using deep learning and machine learning tools to develop medicines in Silico, as the name implies, for the last decade and a half. And yes, they are sometimes filing applications a week after a big pharmaceutical company does. But that kind of debunks the whole thing where this is just a China issue or will always be a China issue.

There’s a lot of companies out there today, startups, American startups, that are actually trying to create entities, at least they’re touting the ability, to displace and short-circuit the entire R&D model that the big pharma industry has grown up on to be able to do everything more efficiently on a computer. And then the third thing is, is it a patent issue? And I would say that there may be some patent elements, but it turns out that a lot of these cases of fast following are because of trade secret theft, employees leaving one company and going to another, whether it’s in the United States or China.

A lot of these assets, the fast following assets, are getting into the labs faster because they’re doing clinical trials in China, where the regulatory system is that much more efficient and lenient. And that may be something we need to learn to adjust there. So, I think it’s really important as a starting point to say, what are we talking about when we say patent scraping is happening?

Is this really what’s going on here? And to the extent it is or will, and I do think it will come, don’t get me wrong. I mean, I’m not naive.

Like, it’s coming. But then the question quickly becomes, what’s wrong with it? I mean, if people are using publicly available information, using the latest tools to be able to create something that satisfies all the patentability criteria, and that’s an important if, but if it satisfies all the patentability criteria, what is wrong with that?

And don’t we ultimately want to become the guy at the desk that can invent the next medicine in three hours instead of, you know, 15 years, you know, with costs that are this small, if it’s actually going to produce a real medicine that matters?

[Gene Quinn] (18:46 – 20:01)

I suppose if you actually invent it, and we’ll come back to that point in a minute. The thing I would like to put a pin in it, because I don’t want to sidetrack this, but I want to just acknowledge it. I do think it’s a China problem.

Now, when I say China problem, I don’t want it to be interpreted that I think China is a problem. What I think it is, this is a China problem from the U.S. perspective, because I, for one, think it is naive to think China is not going to win the AI race. They have more engineers than we have people.

We are now, over the next couple years, likely to engage in some kind of data center slowdown, or at least a slowdown in certain locations, and that is not going to help us. So, I look at this, and not real long term, as AI keeps getting better and better, faster and faster. I think China has an enormous advantage.

Now, if China does not win this AI race, I think it’s going to be more a commentary about capitalism versus their brand of market economics, because I do think you need to incentivize people to take risk in this race, and I don’t know enough about the Chinese system. All I know here is what we get in the U.S., and I don’t know that they’re incentivizing their folks enough.

[Corey Salsberg] (20:01 – 20:11)

I’ll let others chime in, but just to kind of put a pin in this, the question, though, and I don’t disagree with you, but the question is, are we going to regulate our way out of that, or are we going to innovate our way out of that?

[Gene Quinn] (20:11 – 20:29)

Well, I would like to say we’re going to innovate our way out of that, hopefully, but I don’t know that I really believe that. I mean, that’s the solution, I think, but I wonder. We got a question we’ll get to in a minute, but I want to get Nick and Emily to chime in on this round here.

Emily, thoughts on what the guys have said?

[Emily Johnson] (20:31 – 21:35)

So, yes. So, I view this, it is partly a China issue, but it’s also partly a failure of the U.S. system to be appropriately rewarding innovators for the full scope of their inventions. So, given that we have a publication occurring after 18 months in the patent office, the fact that AI is now allowing design around to happen faster than ever before, and post-Amgen v. Sanofi, an innovator can only get claims to embodiments that it’s actually made and tested, but the patent often discloses much more information than that, and it’s that gap in the patent protection and the disclosure that allows fast followers to exploit the lack of coverage. So, I view this as largely a failure of the U.S. court system, and the need to fix Section 112.

[Gene Quinn] (21:36 – 22:00)

So, I’m all in blaming the courts, because they have gotten a lot wrong in this space, and it’s like they don’t understand, they’ve been, and on the Federal Circuit in particular, those of them who were scientists, not all of them were, but it’s like they’ve been scientists so long ago, they forgot what it means to innovate and be scientists, and they just don’t treat it like they know frontline what’s actually happening.

[Kwame Mensah] (22:01 – 23:01)

When we talk about full scope of the invention, are we asking the patent office to give us more than what we’ve claimed, and what I say about that is when you draft a patent application, you know you should be thinking about how many inventions do I have in here, and how many sets of claims can I get to get these inventions, and so if you have something in your patent application that you don’t think you can claim because of the enablement standards we talk about, and then let’s say a fast follower comes along and builds that out, and then they’re able to get claims, have you really, have they really gotten anything that they shouldn’t have gotten, because did you actually have the full scope of that actual invention, and so that’s just, that’s something I would want you to dig in on a little bit, because if I’m drafting a patent application, I am getting blood out of an orange, right, I’m getting every single claims that I can get, and making sure that each one of those claim sets is enabled, so I guess I’m wondering where your distinction is there between what’s not being able to claim versus what is.

[Emily Johnson] (23:02 – 24:10)

Well, there, I think we understand, for example, in like the antibody sciences, that once you find one antibody that binds to the target, it’s very easy to run a competition assay and find dozens and even hundreds of like antibodies that also bind to that same target and have the same functionality. In the Amgen v. Sanofi case, they disclosed dozens of examples.

The claims were broader than that, but a person in antibody sciences would be able to read that disclosure to be able to make hundreds of antibodies. That’s, unfortunately, the court invalidated that claim for being too broad, because there were only 24 examples disclosed in the specification, so I think that’s a perfect example of where Amgen invented a class of antibodies much broader than 24, and a fast follower could come along and, you know, make a minor tweak to an antibody falling outside of the 24, and then you have a fast follower on your hands.

[Gene Quinn] (24:11 – 24:50)

So, let me throw this out there, because I think this may be what you’re talking about, Emily, and where we’re getting to. Like, if you file, and again, using that application in the Amgen case, since we know what the outcome was and what the decision is, and most of us probably have some understanding of what was involved there. As I understand it, and you were at Amgen at the time, so correct me if I’m wrong, but as I understand it, the argument was made against you that it would take a very, very, very long time for somebody to come up with all of the different inventions that were properly disclosed and would be understood by one of skill in the dark, correct?

[Emily Johnson] (24:51 – 24:51)

Correct.

[Kwame Mensah] (24:51 – 24:57)

But let’s be careful about what the court said in their interpretation, because we said they had a tendency to screw that up, right?

[Gene Quinn] (24:57 – 26:29)

Right, right, no, no, no, no, they said, right, no, no, I get, I get, what I was going, like, based on what was at the evidence at trial was, is it was going to, and they didn’t say that, that was not the test for enablement, the long time thing, that was just, so I’m using this as a factual, so I’m not trying to say or mischaracterize what the Supreme Court ruled, but that was, I think, argued definitely would take them at extremely decades, I think is what they said, to come up with all of this, right? So now, in a world where you, the priority date, which is where I wanted to go here, matters so much, and you have to file these things, and you have to file and cover what it is that you have, and now we have a better understanding of what that means after the Amgen case.

You’ve always had to get the priority date on file as quickly as possible, and so how do you square the circle where if it literally is going to take more than a year, because if it’s under a year, then file it as a provisional, and then, you know, keep filing as provisionals until the one-year anniversary, but if there’s so much there, if it’s such a big, broad innovation, and you can’t do that, that seems to be the space what we’re talking about here is potentially the fast filers can exploit, because you need to get the priority date, but you have to wait, but you can’t wait, and if you do wait, it’s only up to a year with creative use of provisionals, and what is that going to mean?

[Corey Salsberg]

You’ve got 18 months.

[Kwame Mensah]

Yeah, you do have 18 months. I think it also goes back to what is…

[Gene Quinn]

Well, 18 months for going public, but not 18 months to claim the priority.

[Corey Salsberg] (26:29 – 26:39)

Right, but there’s no fast… I mean, your concern about scrapers and fast followers shouldn’t be there during that time when it’s not public.

[Kwame Mensah]

Yeah, and what is…

[Corey Salsberg]

Unless they’re truly innovative, and they’re just coming up with things on their own.

[Gene Quinn]

I see, I see what you’re saying.

[Kwame Mensah] (26:40)

Yeah, and what is this full scope of enablement? So, 24 examples is a lot of examples when there are, let’s say, possibly 100. If there are 100,000, is 24 enough? So, let’s take this to its logical conclusion. If I come up with one, let’s say, amazing GLP-1 peptide, so taking that to its crazy conclusion, because I found the one, and anyone else could make peptides that bind GLP, no one else should get a GLP-1 peptide, right?

So, we have to think about that from the perspective of enablement is there to allow for space to innovate. It’s there to allow for you to get what you deserve, right? And so, are we innovating to the… You know, I don’t want people to think that I’m taking a position saying that we can never get broad claims. Of course, but we have to think about what does that mean, and how is the patent office, and how are the courts going to interpret enablement, right?

[Corey Salsberg] (27:34 – 27:35)

Yeah, most of those speeches are going to be garbage.

[Kwame Mensah]

Correct.

[Gene Quinn] (27:36 – 27:41)

So, but it seems like, unless I’m missing something, you guys are now arguing my side.

[Kwame Mensah]

No.

[Corey Salsberg] (27:41 – 27:43)

No.

[Kwame Mensah]

No.

[Corey Salsberg]

No, we’re not. No, we never do that.

[Gene Quinn] (27:43 – 27:45)

I know you would never do that. That’s why I’m trying… I obviously don’t understand what you’re saying.

[Kwame Mensah] (27:45 – 27:50)

We’re saying that you can get broad claims if you deserve broad claims, right?

[Gene Quinn] (27:50 – 28:14)

Right, and it’s an enablement issue. I mean, maybe this is the vehement agreement part of the panel, because I do think we’re almost saying almost the same thing, and maybe I’m a little bit more concerned of where this is headed, but before we get too far, I want to… Nicholas, put some actual prosecutor 101 on us here, and explain, like, what are we saying here that makes sense? What are we saying that you think doesn’t make sense in this current patent office environment?

[Nicholas Lanzatella] (28:15 – 29:59)

Well, you know, it’s hard for me to think about the current environment with how rapidly things have been changing. I guess a couple thoughts that keep going through my mind as I listen to this discussion is, I think it’s easier to talk about obviousness, I mean, which is one thing that can protect against fast followers is the difference between what they’ve done and what you did in your pioneer filing. Is that a big enough gap for it not to be obvious?

I wonder if that measure, the yardstick for that gap, is going to change soon, or should change, because, you know, if we do reach AGI or ASI, right, super intelligence, and most chemists have access to that, then shouldn’t the person of ordinary skill in the art standard, all of a sudden, it’s not really a person anymore, it’s more like an AI of ordinary skill in the art, and that sort of increased standard could help protect, you know, pioneer filers from these sort of piggyback follow-on.

Maybe there’s a similar statement that could be made about enablement. If most people have access to AI tools, does that make it easier for someone to use a smaller set of examples to derive, you know, support enablement for broad claims? Maybe it affects that too.

I wonder how many of these things will evolve, and I wonder if the legal system will be able to keep up with it, and if more is going to be a question of what things should be, rather than what they actually are.

[Gene Quinn] (30:00 – 30:56)

Well, and also inventorship, which is something I think you wanted to specifically talk about too, is how do you, how does the fast follower, and this won’t be true all the time, but how does a fast follower demonstrate that they actually conceived anything? And not to suggest that some of them won’t or haven’t, but if you’re basing it off of a public disclosure from, let’s just say, one of your three companies up on the stage here, right? And your folks have spent, in some cases, a decade working on this, right?

If you take like the MRNA vaccines that we talked about during the first panel today, which led to the COVID vaccines, those were 20 years in process, 20 years. So, you work on this an extraordinarily long time, then it gets published, then somebody’s sitting behind a computer in three hours, winds up going, what could they possibly have contributed in terms of conception in three hours?

[Corey Salsberg] (30:56 – 30:59)

I don’t like that question.

[Gene Quinn] (31:01 – 31:01)

Well, why? Because it makes me seem right?

[Corey Salsberg] (31:01 – 32:24)

No, no, I don’t like that approach to the problem, and here’s why. Because there’s never been, at least not since 1952, a sweat of the brow type test for conception and innovation, right?

You can invent the world’s greatest invention in 12 seconds, and it can be just as valid as something that takes you 40 years.

[Gene Quinn]

Okay, I agree, I agree, but did you invent it?

[Corey Salsberg]

So let me take that on. The hallmark of conception, and this is why we’re very, I get very concerned about some of these so-called solutions to this patent scraping by saying, let’s redo inventorship law, let’s make sure that AI can’t, you know, if you use AI, you’re not an inventor. The hallmark of conception is recognition and appreciation of what has happened. If you can use an AI tool, and you are actually the first to recognize and appreciate the novelty and utility of a particular version of something else that came before, the same thing happens when you inject a xeno mouse with an antigen, and you’re scanning through antibodies, you haven’t done anything except for, you know, look at the results, and you pick one, and you say, hey, that one’s interesting, I’m going to, I’m going to patent that one, and then more importantly, in every one of the cases we’ve seen so far, and then maybe this will change, but these are companies that then actually put them into the clinic, and are developing competing products, so they’re obviously at some point, and along the line, they are contributing something. It may be a lesser than a pioneering invention, but that’s always been the case with a fast follower or a me too type.

[Gene Quinn] (32:25 – 33:08)

Okay, so we do have a question here, you wanted to get to this for a while, so go ahead. So let me try and paraphrase that a little bit so that we get this on the tape, because I’d like to kick this around with you. So the question basically is about obviousness, and the way I would kind of paraphrase this is, are we going to be in a situation where it’s not about, is this obvious to one of ordinary skill, or is it going to be obvious to a super intelligent supercomputer that everybody really can have access to, in which case then everything, presumably, maybe not everything, but most things will become obvious in light of that standard, and that’s a problem not only with the super-fast followers, but I think that’s just a problem in general where this could go.

[Nicholas Lanzatella] (33:09 – 34:26)

You know, it goes so far into the future that I don’t know if I’m comfortable thinking that far into the future, right, because we could start talking about, you know, these are the unpredictable arts that we all work in, how long before they become predictable arts, when a machine can model every part of the body, and every way that a chemical can interact with a protein and whatnot, but, you know, at least for the immediate future, so I think it’s a hard question to answer.

I’m sure others have some thoughts on it, but one comment I would have is, you know, one of the hallmarks of non-obviousness is unexpected results, right? You find something surprising that couldn’t have been predicted, and, you know, I mean, every person who drafts patent applications learns to highlight that data and call it out throughout and surround it with disclosures such that if it becomes an issue, you have lots of ammunition to use against it, that, you know, to highlight that as a reason for patentability to lubricate your path to issuance, you know, that lesson becomes more important than ever now. Assumedly, you’re working on a new class of materials, there’s some advantage to it that needs to be highlighted, and that’s going to be the crux of the battle with the examiner later.

[Kwame Mensah] (34:26 – 34:47)

Yeah, and I would say that, you know, this is going to sound a little bit flippant, but just if you argue the Graham factors and you have the ammunition, you will get over the rejection, right? So, it goes back to my original point of, like, we need to think about how we’re building our patent applications in this new space so we can continue to get coverage and the disaster scenario becomes less of a, you know, a likelihood.

[Corey Salsberg] (34:48 – 35:12)

Yeah, I would say the test really isn’t whether you could do it, it’s whether you would have done it, and my guess is that not everybody’s going to be synthesizing, you know, the same medicines or the same molecules at the same time. You have to have a reason to do that, so I agree. I mean, I think it’ll sort itself out, and look, if at the end of the day, you know, AI is going to do all this for us, then we can all retire and drink pina coladas on an island together.

[Gene Quinn] (35:12 – 36:57)

Well, so, but, okay, let’s talk about that because we won’t be able to do that if there’s not some kind of rights that is being owned, capable of being owned by the company that we’re expecting to spend several billion dollars, maybe more, maybe a little less, but in that ballpark to get all the way through the clinical trials and get to market, and I wonder whether, and certainly in the U.S. and during the next couple years, I think you all in the life sciences industry are in for a tough road. I don’t think what’s going to happen in Congress is going to be to your liking. Maybe we need some kind of sui generis protection, which we’re not going to get here because if there’s not patents and it does become everything’s obvious and everything like this happens, then you can’t invest in it, and if you can’t invest in it, you certainly aren’t going to get it, and I worry about that, but Colin, you had a question?

So, the question basically is about pioneering inventions and whether historically those pioneering inventions may have been entitled, justifiably so, to broader coverage, and that does not seem to be what we see now and probably is not likely moving forward in the future, and again, I think it comes back to some extent to drug prices, right? All these things are, you don’t want to give broad protection. Well, why?

I don’t think it’s just they don’t want to give broad protection in a vacuum. It’s they don’t want to give broad protection because they don’t want you all to be able to own the patent on it so that they have this concept that it’ll be go into the public domain, it’ll be generics, and in the U.S. nine out of ten drugs are generic.

[Kwame Mensah]

I don’t think it’s that nefarious.

[Gene Quinn]

Well, no, I don’t know. I don’t want to call it nefarious, but would you agree that there is that viewpoint that we need more generics, not more brands?

[Kwame Mensah] (36:57 – 37:03)

I think that there may be that viewpoint, but I don’t think that’s related to patent prosecution. I don’t. I think that…

[Gene Quinn] (37:03 – 37:04)

No, no, okay, all right.

[Kwame Mensah] (37:04 – 37:04)

I would agree.

[Gene Quinn] (37:04 – 37:13)

Okay, okay, but what I thought, and that may not be related to patent prosecution, but do you think that’s going on in the minds of the judges?

[Kwame Mensah]

You mean for the enforcement piece?

[Gene Quinn]

Yes.

[Kwame Mensah] (37:13 – 38:09)

Well, I mean, you know, again, I will say that these are the opinions of my own and not of AstraZeneca’s. I would say that as someone who works in this space and is competing in this space, and we’re trying to all find medicines.

For example, for 10 years I led our cancer biologics portfolio, and we are all going after the same targets, and ultimately the reason that these drugs do well is because they’re the best drug, right? Think about how many PD-1 antibodies there are. Think about how they’re…

Like the best drug wins, and that is completely separate from patents. I would hate to live in a world where I was not able to find the best drug in a class because someone has gotten a massively broad patent application that maybe they didn’t deserve. If they deserve it, great.

If the data are there, fantastic. I’m all for that, but we have to live in a world where there are boundaries around what you can get based on what you have in your patent application.

[Corey Salsberg] (38:09 – 38:10)

So, I would part with you a little bit. Sorry, Emily.

[Emily Johnson] (38:10 – 38:11)

Go ahead, go ahead.

[Corey Salsberg] (38:11 – 38:25)

I’d part with you a little bit on that. I mean, I do think the law has gone too far. I agree with you. There should be limits, right? You need to meet an enablement standard. You need to meet a written description standard to the extent that is separate from enablement, which is another debate.

[Kwame Mensah] (38:25 – 38:25)

Which is not, unfortunately.

[Corey Salsberg] (38:26 – 40:14)

But I think it’s gone too far, and I think that it is very difficult now to get broad enough claims and the claims that you should be getting. And I think when you do, to me, the solution is about remedies, right? There shouldn’t…

And under eBay, I’m not supporting eBay. We don’t like that decision. But if there’s two different innovative medicines and they’re both covered by a broad patent claim, the solution, one way or the other, should be a royalty, a remedy, right?

I’m not saying injunctions never, but that usually is the reality, right? With a public interest factor, it’s how a lot of things sort themselves out, and I think should. But I do think that 112 is part of the problem here.

And it’s interesting that this conversation has drifted away, which I like, from the patent scraping idea as being a big problem by itself. I think the bigger problem, frankly, are things like 112. It’s the way that our law has made it more difficult for pioneers to actually get the fair scope that they’re entitled to, which goes back to, what is the solution?

To me, I don’t want to fast forward too much, because we still have some time, I think. But partly, it is dealing with our laws and returning them at least somewhat back to what they were, maybe not all the way. And secondly, is to take advantage of that, take advantage in the positive way, and innovate ourselves, and make sure that we’re actually enabling, using AI tools maybe, broad enough scope so we can actually rest assured that what we’ve invented will be protected.

And if someone else makes some species of it over in China or anywhere else, A, it’s not likely to be as good, because the chances of coming up with the best medicine within a class are slim. And B, if they do, then okay, we have a better drug and it’s fair competition.

[Gene Quinn] (40:15 – 40:24)

So, Emily, can I cross-examine you for just one second? Would you agree with Corey when he says that it’s harder for brands engaging in pioneering research to get the broad protection that you all think you deserve?

[Emily Johnson] (40:25 – 40:25)

Yes, no doubt.

[Gene Quinn] (40:26 – 41:00)

And is that, you think, at the root of why you have concern about the fast followers? Because it would seem to me to be, and I share that viewpoint, I think it’s gotten much harder for you all. And when you should, I think with starting with that viewpoint, and then you look at, well, fast followers are going to be entitled to what?

Anything? When you guys who have come up with it from the ground up are finding it harder and harder to get the full extent, it just feels wrong to give any of that piece to somebody who spent a couple hours in front of a terminal.

[Emily Johnson] (41:01 – 42:38)

I fully agree with you, Gene. I think we need a system that rewards the first mover and the first person to discover that a target is druggable. Because that takes decades, it can be 10 to 15 years, billions of dollars of very risky research that often fails.

And if we remove that incentive by not allowing the inventor to reap a period of exclusivity, nobody is going to do that very important and risky type of work. Everybody will turn into copyists. And so, I think for the sake of our society, we want our laws set up in a way that encourages companies to take that risk.

And the best way I know how to do that is to give them broader claims. That’s the way the United States became the leader in biotechnology. That’s the way our system has worked for the last 40, 50 years.

And under that system, the first mover did get coverage through broader claims. And then the folks who wanted to make a copy or a predictable variant would take a license. To Corey’s point, it was just a remedy issue.

The innovator was being compensated for the use of their discovery. So that’s where I’d like to see the law of return. And I think that would solve a lot of this fast follower issue.

[Gene Quinn] (42:39 – 42:58)

So, it does. And I do think, I think what we’re putting our fingers on here is agreement, I think. Kwame, maybe not you, but I don’t want to put words in your mouth, but do you also believe that it’s harder for you as an innovator to get the broad protection that you feel like you deserve?

[Kwame Mensah] (42:58 – 43:08)

Yeah. I mean, I think it’s harder to get broad protection. And to be honest, I don’t think this is new.

[Gene Quinn]

No.

[Kwame Mensah]

I mean, it’s been going at least 15, 16, 17 years.

[Gene Quinn] (43:08 – 43:09)

But it’s gotten worse, correct?

[Kwame Mensah] (43:09 – 43:55)

I would say it’s gotten worse, but I think also, speaking for myself, I’ve adjusted my prosecution style. I’ve still been able to get broad claims, maybe not as broad as in 2007, but I’ve still been able to get some breadth of my claims. So, it’s a balance.

And I do agree that we can talk about where the law has gone or where it’s not gone, but we do have to function within the parameters of what that is. And I do think that there is still space for innovation. I think there’s still space for a first mover advantage, and those lies in two things.

One, 18 months, right? So, if it takes 18 months plus three hours, apparently, to have that advantage. And then also keep innovating the best drugs.

The best drugs give you the best data, which gives you the strongest patents. It’s in that order, right?

[Gene Quinn] (43:55 – 45:47)

Right. But now let me ask you this, throw this out to all of you about the idea that came up earlier today about evergreening and patent thickets. And it seems whatever strategy you all might be able to follow in order to make things better for you to get the protection that you need, there is some pejorative name that gets thrown at that, that then you get held up as the problem, not the solution.

And I wonder, because I think you’re right. If you have 18 months to constantly churn your own disclosure, using AI to be your own fast follower, then what you’re going to wind up doing is you’re going to wind up with way more patents probably than you currently have. And this is not news to any of you all in the audience, but those who might be listening to this that are not in the life sciences industry.

Life sciences companies, in my opinion, have shockingly small patent portfolios, you know, but I’m a computer guy, right? I mean, it’s wholly different orders of magnitude. And I’m not suggesting that you guys will wind up having like a semiconductor level of portfolio, but you will, if you do this and be your own fast follower, your portfolios will grow two, three, four X, perhaps, right?

And in that world, I just see the people marching with their signs down in DC, which they actually do over patent issues. Can you believe that? And they put on billboards in DC and on bus stops and on buses, patents kill, you know, all that sort of thing. I can see that just being exhibit A in Big Evil Pharma, they’re patenting now 4X what they used to patent, and it’s just getting in the way. And so the strategies that would work from a legal IP business perspective are going to backfire on the public policy.

[Corey Salsberg] (45:47 – 46:52)

I think that that is a risk, although that’s already, as you point out, the reality we live in. But I also think that hopefully we can educate lawmakers on both sides of the aisle about how the alternative is what we’re worried about now, right? Is China’s going to outcompete us and all those inventions are going to go to foreign entities instead of ones based here.

And I think they shouldn’t be competing, but they’re two separate narratives, and I think that they need to be squared. Also, I’m not convinced that it has to be more patent, and there’ll be some more patents. It’s also, we’re talking about broadening the scope of a given patent, right?

So that a claim that is a functional antibody claim, just for example, maybe it becomes supportable either through legal changes about where 112 becomes a little more flexible again, or through technological change, where you’re able to use these increasingly sophisticated tools to enable a broader scope of your claim to begin with, and you satisfy the enablement test because we have the technology to say now it’s no longer, now it’s just routine experimentation and not undue experimentation.

[Gene Quinn] (46:53 – 48:00)

So, Nicholas, let me ask you this, and this maybe isn’t, I think I’ve thought this through enough to throw it out there, but kick it around. If you don’t want the more patents, like Corey said, maybe it won’t be more patents, maybe it will be some more patents, I think it would be better for them in the audience and the companies not to have more patents for a variety of the public policy reasons. Could you file that application, it stays secret for 18 months, before that 18 months you’re spending your time being your own fast follower, and then they come to you and they say, let’s file the next application, it’ll be a continuation in part on the first application, and now that we have all the data to support all of the stuff that we didn’t know back then, we got the priority date for the first filing in place, and now we’re going to file a whole lot more into this continuation in part, knowing that that’s going to have term repercussions for at least the stuff that gets added, right? Is that maybe a solution or not?

[Nicholas Lanzatella] (48:00 – 48:29)

Well, I mean, for the U.S. only, right, the CIP is a U.S. phenomenon, and pharmaceutical companies are global, so I mean, I think the answer is no, and I just want to put on the record, I think most of us agree more patents is a good thing, and that’s too bad if the public looks down on that. I don’t think there’s anything wrong with filing a lot of patents, and I think there’s probably counter-arguments to any public view that that’s a negative. For sure.

[Gene Quinn] (48:29 – 48:42)

Well, amen on that. I’m glad you brought that up, because I do think once upon a time, the number of patents was a proxy for how innovative the company was. That’s not the craziest proxy in the world. I mean, that actually is a proxy that makes sense.

[Corey Salsberg] (48:42 – 48:50)

And let’s also not forget that more patents doesn’t mean longer patent term. I mean, there have been, we’ve had many, many panels at IPWatchdog on this and elsewhere, right?

[Gene Quinn] (48:50 – 48:53)

Well, there you go injecting facts into a religious argument.

[Corey Salsberg] (48:54 – 49:36)

It’s always a mistake, but the patent term has stayed, effective patent term has stayed constant for decades. It’s going to stay that way. It may even go down, because we’re going to face other innovator-to-innovator competition increasingly.

We see this with the GLP-1s, for example. So, I think that we need to keep at it and point out that the number of patents is a meaningless statistic. What should matter is, is the system functioning as intended to have the right balance between innovation and eventually people entering the public domain?

And the answer on the data is, of course, yes. I mean, we get 12 to 14 years or something like that, 11 to 13, whatever it is, depending on the study, but well below the 20 we’re supposed to get.

[Gene Quinn] (49:37 – 51:13)

Excellent. So, question. So, the question is about whether or not the existing model for a lot of AI companies is to use tokens in order to pay for these more advanced processing, and whether or not that is a natural throttle on what it is that we’re talking about here. Now, I’m going to take the first stab on this, because I have thought about this a lot, and we’ve done a lot of webinars on these types of issues, and I am a computer guy.

I think maybe at the moment it is a throttle to some extent. I think it will be a throttle for an enormously short period of time, because I will predict, and I feel as certain about this prediction as I’ve ever been about anything, is that tokens are going to be, maybe by this time next year, certainly in two years, we’re not going to be talking about tokens anymore. If AI is to thrive the way that we want it to thrive, and the business is going to grow the way that the companies are valued at already, they cannot charge people for every time they use something.

Because if they do that, they will use it less, not more. And they’re still in a phase where they need to be racing to get adopters, racing to get people more and more dependent. I use it all the time.

Nicholas uses it all the time. You all use it quite often as well. But how many people in the world use AI as frequently as us power users?

That’s where the growth of these companies, companies are already valued at trillions of dollars, or they will be as soon as they go public. For that valuation, a token-based business model can’t sustain that value.

[Nicholas Lanzatella] (51:15 – 52:33)

Well, first off, I mean, I think that with skillful prompting, you can get an awful lot done for 2 to 4K of tokens, an awful lot. So yeah, it’s a barrier to some extent for somebody who’s not serious. But anybody who’s even a little serious and appreciates the potential profits, 2 to 4K, no problem.

So that’s one. Second, to respond to some of Gene’s comments, I know I’m not an expert on this, but my understanding is a lot of the AI companies are taking a loss on compute time right now. They’re charging us less than it actually charges, than it costs them to do the computer work that you’re requesting.

And part of that system is to get everybody using AI. And then once the prices do go up, which, you know, I don’t know if they’re going to go up or not. If they can build all the data centers, maybe not.

But if they can’t, then maybe those prices will need to go up. People won’t be able to say no, because they’ll be so integrated into their work processes that some increase, you know, would be acceptable in order to maintain the status quo that they’ve gotten used to. So, I’m not sure what’s going to happen with token prices.

I hope they go down. I hope they do.

[Gene Quinn] (52:34 – 53:35)

I think they’re going to go away entirely. I mean, because if you have to pay for something, take for a minute total cascade thought for a minute. Why do we have income tax?

Why don’t we just have sales tax? Why don’t we every time we go and buy something, you have sales tax? Well, because then you see it in everything that you buy and people would buy less.

I mean, the studies are all over the place that if you have a sales tax as your consumption-based tax, and it’s easily observable, people buy less. I mean, and so there will be a time when these tokens, people are looking at these tokens. Yeah, I’d really like to do that, but it costs these amount of tokens.

And these AI companies, and maybe they’ll eventually get to the point where it doesn’t matter to them, but they’re looking for the world domination in trillion dollar markets. They need as many users as possible. They’re crack dealers right now.

They’re losing money, just like Nicholas said, on everything they’re doing, but it’s cracked for us. And eventually we’re not going to be able to think anymore without AI, right? So, Corey, did you want to say something?

[Corey Salsberg] (53:35 – 55:29)

No, I mean, that’s hard to predict. I mean, I think there’s offsetting. The costs of using AI, I think are going to go up over time.

The question, I guess, is who bears it? I think it’s not just the energy cost, but it’s also the cost of developing new AI tools, right? Because right now, the tools we have, again, I go back to, is this a problem today?

If it is, it’s a small problem. I think the bigger, this panel really is about the future. What’s it going to look like? But to get to the point where scraping or other uses of AI, good or bad, are going to really displace everything that we know and love, that requires new tools to be developed, and that’s going to have costs as well. So, I think it’s a hard thing to predict. I take your word for it.

It sounds like you’ve done a lot of thinking here. But to me, I think the bigger limiting factor here is really what is the business model of fast followers, right? Are there going to be a few who do this to extort the real patent owner to try to get a quick license, almost like a reverse patent troll kind of thing, maybe?

But there’s also going to be those who are trying to actually compete and create a molecule that’s better than yours, and that’s not going to be easy to do. I mean, you can scrape all the patents you want, but as we just said, as it is, we the experts who pioneer these things, it takes us 10 to 15 years to figure out which version of this is actually going to be the good one. So, someone could get lucky, but most of the time, if they’re just deciding to patent a few particular species of your genus, the chances that that is going to be the better product than yours are slim.

This was the GluBio thing in the article in the Wall Street Journal that involves one of our products, one of your products, and GluBio Therapeutics are small startup products. There is apparently, at least I haven’t looked into it myself, but they’re trailing that candidate, you know, BMSs and Novartis. So, I think you’re going to have the natural realities of the marketplace that will also help to limit some of the appeal of people abusing the system on this, but we’ll see.

[Kwame Mensah] (55:29 – 55:51)

So, say back to the point of like, you know, of course saying best drug wins, what, 14% of drugs get through phase three, something like that, right? So, if they increase it to 17%, I mean, it’s still a high, high, high bar. And so, while I definitely understand that these sort of fatalistic scenarios are not impossible, I guess I’m not as worried about it.

[Gene Quinn] (55:51 – 56:14)

Damn it, weren’t you here earlier when I said doom and gloom sells? It gets eyeballs, damn it Kwame. Reasonableness.

All right. So, we’re running a minute late here. So, what I would like to give each of you one last opportunity in truly rapid fire, and we can start with you, Nicholas, and go down that way. What is your final takeaway message for the audience?

[Nicholas Lanzatella] (56:15 – 56:35)

Final takeaway, be your own fast follower. Absolutely. And, you know, we didn’t get a chance to talk that much about inventorship today, but you should, if I was advising a pharmaceutical company, I would tell them to document human conception when AI is playing a big part in the invention discovery process.

[Gene Quinn] (56:36 – 56:37)

Awesome. Thanks, Nicholas. Emily.

[Emily Johnson] (56:37 – 57:08)

Okay. I think we want to keep the door open to public disclosure of inventions and the ability to design around and improve upon those discoveries. But we also need to ensure that pioneering discoveries are fairly rewarded and compensated through the patent bargain.

If not, we’re going to move towards a situation where innovators are not going to be publicly disclosing their work, and I don’t think that’s a good thing for patients.

[Gene Quinn] (57:08 – 57:12)

Yeah, we didn’t touch on that, but I have that concern as well. So, thank you, Emily. Kwame.

[Kwame Mensah] (57:12 – 57:35)

Yeah, I would say everyone just be smart patent drafters. Think about the disclosure you should put in, as Nicholas would say, like set up your arguments. Think about enablement. Think about obviousness. Think about the types of data you put in patent applications. And I think that will hopefully give us the ability to get broader claims than we’ve been able to get recently.

[Gene Quinn]

Awesome. Thanks, Kwame. Corey.

[Corey Salsberg] (57:35 – 57:40)

I would say just calm down.

[ Gene Quinn]

Take a chill pill, Gene.

[Corey Salsberg] (57:40 – 57:41)

Take a chill pill, Gene and others.

I think, look, this is one of the many potential negative sides to AI, but it also comes with the positive benefits of AI. I think we need to take the time to see what’s really happening, to study it better, and most importantly, to really, really slow down and think through the proposed solutions, because we have heard everything from, let’s make you disclose every single use of AI in every patent application going forward, which would be a disaster. Let’s ban all applications from China, which would be a disaster, because they’d do the same to us.

Let’s make it so you can’t have prophetic examples anymore, which we rely upon in our real work. I mean, you really need to think about the trade-offs of all these different solutions if we’re ever going to address this problem, and also just see what happens.

[Gene Quinn] (58:26 – 58:54)

Well, that was a great conversation. I really appreciate it, guys. I had a lot of fun, and I think, for sure, this is going to be, you’re going to see this again at IPWatchdog Live.

You could tell with the audience engagement and with the way we did it here, and I think we could have probably the same people on the same panel in April, and it would be all different. We’d just start, wind each other up, and we’d get going. It’ll be interesting to see how this develops but thank you so much for a wonderful conversation.

[Renee Quinn] (58:54 – 59:12)

Thank you for listening to IPWatchdog Unleashed. We will be back next week, and we hope you will join us again. In the meantime, please be sure to visit IPWatchdog.com to read all the latest news and information about what is happening in the intellectual property world, and also be sure to subscribe to our free daily email newsletter.